Clinical Trial on Agitation in Alzheimer's Dementia

Launched by IGC PHARMA, LLC · Sep 14, 2022

Keywords

ClinConnect Summary

The IGC-AD1 Trial is studying a new oral medication called IGC-AD1, which is made from a natural compound found in cannabis known as THC. This trial is designed to see if taking this medication, in small doses twice a day, can help reduce agitation in people with Alzheimer's disease. Agitation can include feelings of restlessness, anxiety, or aggressive behavior, which can be challenging for both the patient and their caregivers. The trial is currently looking for participants aged 21 and older who have mild to severe Alzheimer's and are experiencing significant agitation.

To participate, individuals need to have a caregiver who can help with the study procedures, and both the participant and caregiver must agree to join by signing consent forms. Participants will need to meet certain health criteria, such as having a diagnosis of Alzheimer's and showing signs of agitation, but they should not have serious medical conditions that could affect the study outcomes. Those who qualify can expect regular visits and assessments to monitor their health and response to the medication. If you or a loved one are considering participating, it’s essential to discuss it with your healthcare provider to understand all aspects of the trial.

Gender

ALL

Eligibility criteria

• To be eligible to participate in this study, the participant must meet all the following criteria:
• • Inclusion Criteria
• • 1. Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.
• • 2. Must have a Caregiver who is able and willing to comply with all required study procedures.
• • 3. The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.
• • 4. Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.
• • 5. Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.
• • 6. Diagnosis of AD by NIA-AA criteria
• 7. Clinically significant Agitation assessed by:
• • 1. NPI (Agitation) ≥ 4
• • 2. The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and
• • 3. Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.
• • 8. Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.
• • 9. All medications used for behavioral symptoms should be consistent for at least 3 months before screening, with allowance for dose changes up to 25%.
• • 10. Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • Exclusion Criteria
• • 1. Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo): THC, melatonin, honey, curcumin, ethyl alcohol, vitamin-E TPGS, ascorbic acid, water, tween-80, and rutin.
• • 2. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.
• • 3. History of seizures, schizophrenia, or bipolar disorder.
• • 4. Has participated in an investigational drug or device study within 30 days prior to study start.
• • 5. Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least 3 months before screening.
• • 6. History of Alcohol and Drug use disorder, within one year prior to enrollment.
• • 7. Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.
• • 8. Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).